all report title image
  • Published In : May 2023
  • Code : CMI2596
  • Pages : 210
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Hepatic encephalopathy (HE) is the leading cause of mortality in patients suffering from acute liver failure and also in those patients suffering from liver cirrhosis and associated with end stage liver disease. A person suffering from hepatic encephalopathy loses the ability to metabolize ammonia, which results in the buildup of ammonia in various tissues and organs of the body. Moreover, ammonia crosses the blood–brain barrier, and thus causing neurocognitive impairment. Hepatic encephalopathy can be classified into two types: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE), out of which, overt hepatic encephalopathy is associated with high rates of mortality and poor quality of life, as compared to covert hepatic encephalopathy (CHET). The major market participants have developed novel technologies and techniques for treating liver disorders. The market will expand as a result in the coming year.

Increase in the government and non-government organizations initiatives to improve access to affordable liver related treatment option. Rise in the awareness regarding the importance of liver health among the people and favorable reimbursement are the factors likely drive the market growth. For instance,  in October 2022, Bausch Health Companies Inc., and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies announced the endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain

Key features of the study:

  • This report provides in-depth analysis of the global hepatic encephalopathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hepatic encephalopathy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include ASKER Pharmaceutical Co., Ltd, Cosmo Pharmaceuticals N.V, Lupin Limited, Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc, Ferring Pharmaceuticals In, Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V, Abbott Laboratories, QR Science and Technology Development Co.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hepatic encephalopathy market

Detailed Segmentation:

  • Global Hepatic Encephalopathy Market, By Drug Class:
    • Antibiotics
    • Laxatives
    • L-ornithine L-aspartate
    • Others
  • Global Hepatic Encephalopathy Market, By Route of administration:
    • Oral
    • Intravenous
    • Rectal
  • Global Hepatic Encephalopathy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hepatic Encephalopathy Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • ASKA Pharmaceutical Co., Ltd.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Cosmo Pharmaceuticals N.V
    • Lupin Limited
    • Kaleido Biosciences
    • Kannalife Sciences Inc.
    • Bausch Health Companies Inc.
    • Ferring Pharmaceuticals Inc.
    • Mallinckrodt Pharmaceuticals
    • Umecrine Cognition AB
    • Norgine B.V
    • Abbott Laboratories
    • Kos Pharmaceuticals, Inc.
    • QR Science and Technology Development Co.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Route of Distribution
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Recent Product Launches/Approvals
    • Technological Landscape
    • Merger, Acquisition, Collaborations Scenario
    • Regulatory Scenario
    • PEST Analysis
    • Porter's Five Forces Analysis
    • Pricing Analysis
    • Brand Analysis
  4. Global Hepatic Encephalopathy Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand
  5. Global Hepatic Encephalopathy Market, By Drug Class, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    •  Antibiotics
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Laxatives
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • L-ornithine L-aspartate
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Others
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
  6. Global Hepatic Encephalopathy Market, By Route of Administration, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Rectal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Hepatic Encephalopathy Market, By Distribution Channel, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  8. Global Hepatic Encephalopathy Market, By Region, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 – 2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 – 2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 – 2030, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 – 2030, (US$ Million)
        • China
        • Japan
        • India
        • Australia
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 – 2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 – 2030, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • ASKA Pharmaceutical Co., Ltd
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Cosmo Pharmaceuticals N.V.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Lupin Limited.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Kaleido Biosciences
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Kannalife Sciences Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bausch Health Companies Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Ferring Pharmaceuticals Inc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Mallinckrodt Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Umecrine Cognition AB
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Norgine B.V.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Abbott Laboratories
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • QR Science and Technology Development Co.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  10. Section
    • Research Methodology
    • About Us

*Browse 42 market data tables and 35 figures on “Global Hepatic Encephalopathy Market” - Global forecast to 2030

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo